O\'Regan Highlights CDK46 Agents Other Developments in ER Breast Cancer

O'Regan Highlights CDK4/6 Agents, Other Developments in ER+ Breast Cancer

13:09 EST 27 Nov 2018 | OncLive

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.

More From BioPortfolio on "O'Regan Highlights CDK4/6 Agents, Other Developments in ER+ Breast Cancer"